Recently, small-molecule inhibitors of MDM2 and CDK4 (for example, RG 7112, flavopiridol, and PD0332991) have been developed and have shown promising results for the treatment of WDLPS/DDLPS in small-scale phase I and II clinical studies [12–16]. Here, CDK4 is linked to dedifferentiated liposarcoma.